Výsledky vyhledávání - "S. I. Gracon"

Autor: David S. Knopman, Fraser B. Smith, S. I. Gracon, S. Talwalker, T. M. Hoover, Lon S. Schneider, K. Davis

Publikováno v: Neurology. 47:166-177

Objective: To assess the possible association between tacrine (Cognex, manufactured by Parke-Davis, Morris Plains, NJ) dose and likelihood of nursing home placement (NHP) or death in patients with AD. Design: A 30-week, randomized, double-blind, plac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ed18440071f44a7b3ac027ae92a7e415
https://doi.org/10.1212/wnl.47.1.166

Zobrazit plný text záznamu

An Enriched-Population, Double-Blind, Placebo-Controlled, Crossover Study of Tacrine and Lecithin in Alzheimer's Disease

Autor: S I Gracon, K Lewis, R. C. Petersen, Norman L. Foster

Publikováno v: Dementia and Geriatric Cognitive Disorders. 7:260-266

We studied the effects of 40 and 80 mg/day of tacrine on patients with probable Alzheimer''s disease (AD) in an 8-week, randomized, double-blind, placebo-controlled crossover trial with an enriched-population design. In the initial dose titration pha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::12f316d26f6a5ca6793b5af15a1921d6
https://doi.org/10.1159/000106890

Zobrazit plný text záznamu

MRI as a Biomarker of Disease Progression in a Therapeutic Trial of Milameline for AD

Autor: R. C. Petersen, C. R. Jack, Yuecheng Xu, P. C. O'Brien, S. I. Gracon, Ruth H. Cha, M. Slomkowski, Joel P. Felmlee, Maria Shiung, K. Stewart, T. M. Hoover, D. S. Knopman

To assess the feasibility of using MRI measurements as a surrogate endpoint for disease progression in a therapeutic trial for AD.A total of 362 patients with probable AD from 38 different centers participated in the MRI portion of a 52-week randomiz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::409138d4f92d5a57b48ad7f475dd4e85
https://europepmc.org/articles/PMC2745302/

Zobrazit plný text záznamu

An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group

Autor: N L, Foster, R C, Petersen, S I, Gracon, K, Lewis

Publikováno v: Dementia (Basel, Switzerland). 7(5)

We studied the effects of 40 and 80 mg/day of tacrine on patients with probable Alzheimer's disease (AD) in an 8-week, randomized, double-blind, placebo-controlled crossover trial with an enriched-population design. In the initial dose titration phas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::93ec7aa665e48a3c4bc3a7950f461d6b
https://pubmed.ncbi.nlm.nih.gov/8872417

Zobrazit plný text záznamu

A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group

Autor: M J, Knapp, D S, Knopman, P R, Solomon, W W, Pendlebury, C S, Davis, S I, Gracon

Publikováno v: JAMA. 271(13)

To evaluate the efficacy and safety of high-dose tacrine hydrochloride over 30 weeks in patients with probable Alzheimer's disease.A 30-week randomized, double-blind, placebo-controlled, parallel-group trial.Outpatients at 33 US centers.Men and women

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5daf3db45e2d7f3ae059400c9a085946
https://pubmed.ncbi.nlm.nih.gov/8139061

Zobrazit plný text záznamu

Observations on the short-term 'natural history' of probable Alzheimer's disease in a controlled clinical trial

Autor: S. I. Gracon, David S. Knopman

Publikováno v: Neurology. 44(2)

We examined the performance of patients with probable Alzheimer's disease (AD) who participated in the placebo arm of a 12-week clinical trial. Assessments occurred at baseline and at 4, 6, 10, and 12 weeks after starting study medication. Patients r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fbf12f4403c3e8989ac34658b81ed4c
https://pubmed.ncbi.nlm.nih.gov/8309570

Zobrazit plný text záznamu

A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group

Autor: M, Farlow, S I, Gracon, L A, Hershey, K W, Lewis, C H, Sadowsky, J, Dolan-Ureno

Publikováno v: JAMA. 268(18)

To compare efficacy and safety of tacrine hydrochloride with placebo in patients with probable Alzheimer's disease.A 12-week, double-blind, placebo-controlled, parallel-group study.Outpatients at 23 centers.Men and women with probable Alzheimer's dis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5b96cb3ba9377620842160bf6a897bec
https://pubmed.ncbi.nlm.nih.gov/8497088

Zobrazit plný text záznamu

Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease

Autor: N R, Cutler, A J, Sedman, P, Prior, B A, Underwood, A, Selen, L, Balogh, A W, Kinkel, S I, Gracon, E R, Gamzu

Publikováno v: Psychopharmacology bulletin. 26(2)

Neurochemical studies of Alzheimer's disease (AD) suggest deficiencies in the cholinergic system. We evaluated the steady-state pharmacokinetics of tacrine (Cognex), an oral cholinesterase inhibitor, in 12 patients with AD. Patients sequentially rece

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9b4b7154147a349181b651ccf7018791
https://pubmed.ncbi.nlm.nih.gov/2236461

Zobrazit plný text záznamu

Tacrine and nursing home placement

Autor: Lon S. Schneider, S. I. Gracon, Fraser B. Smith, Kenneth R. Davis, David S. Knopman

Publikováno v: Neurology. 49:898-899

Reply from the Authors: Thal and colleagues offer several criticisms involving methodological issues, including the obvious critique of observational cohort studies that the results are those of a "healthy patient" effect "since it is plausible, logi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::88547bd3114368f3d52c25c4f090f8b2
https://doi.org/10.1212/wnl.49.3.898

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání